AMPLI Stock Overview
Amplitude Surgical SA develops and markets products for orthopedic surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AMPLI from our risk checks.
Amplitude Surgical SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.00 |
| 52 Week High | €3.68 |
| 52 Week Low | €2.88 |
| Beta | 0.51 |
| 1 Month Change | -11.76% |
| 3 Month Change | -7.98% |
| 1 Year Change | -11.24% |
| 3 Year Change | 39.53% |
| 5 Year Change | 14.50% |
| Change since IPO | -40.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMPLI | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -3.2% | 1.6% | 1.2% |
| 1Y | -11.2% | 11.5% | 4.0% |
Price Volatility
| AMPLI volatility | |
|---|---|
| AMPLI Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Volatility Over Time: AMPLI's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 388 | Olivier Jallabert | www.amplitude-surgical.com |
Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It also offers AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery.
Amplitude Surgical SA Fundamentals Summary
| AMPLI fundamental statistics | |
|---|---|
| Market cap | €143.96m |
| Earnings (TTM) | -€2.95m |
| Revenue (TTM) | €104.10m |
1.4x
P/S Ratio-48.8x
P/E RatioIs AMPLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMPLI income statement (TTM) | |
|---|---|
| Revenue | €104.10m |
| Cost of Revenue | €51.15m |
| Gross Profit | €52.96m |
| Other Expenses | €55.90m |
| Earnings | -€2.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 50.87% |
| Net Profit Margin | -2.83% |
| Debt/Equity Ratio | 111.1% |
How did AMPLI perform over the long term?
See historical performance and comparison